使用225Ac标记单域抗体进行靶向α治疗可诱导抗原特异性免疫反应并在全身和肿瘤微环境中建立免疫调节
本研究在人CD20和卵清蛋白表达的B16黑色素瘤模型中,使用225Ac标记的抗人CD20单域抗体进行靶向α治疗,通过流式细胞术、脾细胞再刺激和血清多重分析评估免疫反应。结果显示α治疗延迟肿瘤生长、增加多种细胞因子、诱导外周抗肿瘤T细胞反应,并将冷肿瘤微环境调节为更利于抗肿瘤免疫细胞的的热微环境;联合PD-L1阻断增强疗效但加重不良事件,长期毒性研究显示严重肾损伤。
要点
- α治疗延迟肿瘤生长并增加干扰素-γ、CCL5、GM-CSF和MCP-1等细胞因子血浓度。
- α治疗在肿瘤部位减少促肿瘤替代激活巨噬细胞、增加抗肿瘤巨噬细胞和树突状细胞。
- α治疗与PD-L1阻断联合增强疗效但加重不良事件,长期毒性研究显示严重肾损伤。
核心结论
- 这些数据提示α治疗改变肿瘤微环境并诱导全身抗肿瘤免疫反应,这解释了免疫检查点阻断为何增强α治疗的疗效,但需要进一步优化以避免不良事件。
研究设计与样本
- 研究在人CD20和卵清蛋白表达的B16黑色素瘤模型中,使用225Ac标记的抗人CD20单域抗体进行靶向α治疗,通过肿瘤流式细胞术、脾细胞再刺激和血清多重分析研究免疫反应。
主要发现
- α治疗延迟肿瘤生长并增加干扰素-γ、C-C基序趋化因子配体5、粒细胞-巨噬细胞集落刺激因子和单核细胞趋化蛋白-1等多种细胞因子血浓度。
- α治疗后可检测到外周抗肿瘤T细胞反应。
- 在肿瘤部位,α治疗将冷肿瘤微环境调节为更适宜抗肿瘤免疫细胞的热微环境,特征为促肿瘤替代激活巨噬细胞减少、抗肿瘤巨噬细胞和树突状细胞增加。
- α治疗增加肿瘤微环境中程序性死亡配体1(PD-L1)阳性免疫细胞的百分比。
- α治疗与PD-L1阻断联合增强治疗效果,但联合加重不良事件;长期毒性研究显示α治疗导致严重肾损伤。
局限性
- 需要进一步优化以避免不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle-emitting radionuclides (α-TRT) is an intensely investigated treatment approach as the short range of α-particles allows effective treatment of local lesions and micrometastases. However, profound assessment of the immunomodulatory effect of α-TRT is lacking in literature. Methods: Using flow cytometry of tumors, splenocyte restimulation, and multiplex analysis of blood serum, we studied immunologic responses ensuing from TRT with an antihuman CD20 single-domain antibody radiolabeled with 225Ac in a human CD20 and ovalbumin expressing B16-melanoma model. Results: Tumor growth was delayed with α-TRT and increased blood levels of various cytokines such as interferon-γ, C-C motif chemokine ligand 5, granulocyte-macrophage colony-stimulating factor, and monocyte chemoattractant protein-1. Peripheral antitumoral T-cell responses were detected on α-TRT. At the tumor site, α-TRT modulated the cold tumor microenvironment (TME) to a more hospitable and hot habitat for antitumoral immune cells, characterized by a decrease in protumoral alternatively activated macrophages and an increase in antitumoral macrophages and dendritic cells. We also showed that α-TRT increased the percentage of programmed death-ligand 1 (PD-L1)-positive (PD-L1pos) immune cells in the TME. To circumvent this immunosuppressive countermeasure we applied immune checkpoint blockade of the programmed cell death protein 1-PD-L1 axis. Combination of α-TRT with PD-L1 blockade potentiated the therapeutic effect, however, the combination aggravated adverse events. A long-term toxicity study revealed severe kidney damage ensuing from α-TRT. Conclusion: These data suggest that α-TRT alters the TME and induces systemic antitumoral immune responses, which explains why immune checkpoint blockade enhances the therapeutic effect of α-TRT. However, further optimization is warranted to avoid adverse events.
引用
- Ertveldt T, Krasniqi A, Ceuppens H, et al. Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment. J Nucl Med. 2023. PMID: 37055223. doi:10.2967/jnumed.122.264752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。